Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Isatuximab-based Therapy in Participants With Lymphoma
NCT03769181 · Sanofi · PHASE1/PHASE2 · terminated · last registry update 2025-09-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD38 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-15Results posted on the registry: Academic and Community Cancer Research United, Carfilzomib + Daratumumab (NCT04756401)
- 2026-09-11Also stopped (withdrawn): Fred Hutchinson Cancer Center, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 + Cyclophosphamide (NCT04579523)
- 2026-08-28Phase 3 first posted: AbbVie, Etentamig + Daratumumab (NCT07793422)
- 2026-08-19Phase 3 first posted: CellCentric Ltd., InoPd + Investigator's choice of SAT (NCT07772024)
- 2026-08-14Phase 3 first posted: AstraZeneca, AZD0120 + Daratumumab (NCT07764978)
- 2026-08-03Phase 3 first posted: Biocad, BCD-248 + daratumumab + Daratumumab + pomalidomide + dexamethasone (NCT07742215)
- 2026-07-31Phase 3 first posted: Polish Myeloma Consortium, Teclistamab + Talquetamab (NCT07740486)
- 2026-07-29Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, Isatuximab + VRD (NCT07732712)
- 2026-07-28Results posted on the registry: University of Michigan Rogel Cancer Center, Daratumumab + Lenalidomide (NCT04140162)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-07-16Phase 3 first posted: Nexcella Inc., NXC-201 + Dara-CyBorD (NCT07709715)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-25Results posted on the registry: GlaxoSmithKline, Belantamab mafodotin + Isatuximab (NCT07217184)
- 2026-06-24Phase 3 first posted: Janssen Research & Development, LLC, Ramantamig + Daratumumab (NCT07665450)
- 2026-06-18Also stopped (withdrawn): Regeneron Pharmaceuticals, Linvoseltamab + Bortezomib (NCT07428369)
- 2026-06-16Phase 3 first posted: University of Leeds, Daratumumab + Lenalidomide (NCT07649525)
- 2026-06-09Also stopped (withdrawn): UNC Lineberger Comprehensive Cancer Center, Daratumumab + Lenalidomide (NCT06348147)
- 2026-06-03Phase 3 first posted: Dana-Farber Cancer Institute, Isatuximab + Iberdomide (NCT07624513)
- 2026-06-03Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Pomalidomide Capsules + Bortezomib for Injection (NCT07623798)
- 2026-05-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, daratumumab + carfilzomib (NCT03290950)
- 2026-05-22Results posted on the registry: Celgene, Pomalidomide + Dexamethasone (NCT01946477)
- 2026-05-20Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Isatuximab + Pomalidomide (NCT05911321)
- 2026-05-20Results posted on the registry: Weill Medical College of Cornell University, Daratumumab SC + Clarithromycin (NCT04302324)
- 2026-05-19Results posted on the registry: Genmab, GEN3014 + Daratumumab (NCT04824794)
- 2026-05-19Also stopped (terminated): Genmab, GEN3014 + Daratumumab (NCT04824794)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision